Edmond DE Rothschild Holding S.A. Buys Shares of 27,965 Caris Life Sciences, Inc. $CAI

Edmond DE Rothschild Holding S.A. purchased a new position in Caris Life Sciences, Inc. (NASDAQ:CAI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 27,965 shares of the company’s stock, valued at approximately $498,000.

A number of other hedge funds also recently made changes to their positions in the stock. Global Retirement Partners LLC grew its position in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after acquiring an additional 999 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Caris Life Sciences by 839.4% during the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after purchasing an additional 1,469 shares in the last quarter. Fifth Third Bancorp bought a new stake in Caris Life Sciences during the first quarter worth about $31,000. Sterling Capital Management LLC boosted its holdings in shares of Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after purchasing an additional 1,083 shares in the last quarter. Finally, Trifecta Capital Advisors LLC purchased a new position in shares of Caris Life Sciences in the 2nd quarter worth about $37,000.

Analyst Ratings Changes

CAI has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Caris Life Sciences in a report on Friday, August 7th. Citigroup cut their target price on Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Robert W. Baird set a $22.00 price target on shares of Caris Life Sciences in a research report on Friday, May 8th. Wolfe Research lowered shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Finally, New Street Research initiated coverage on shares of Caris Life Sciences in a research note on Friday, May 8th. They issued a “market perform” rating for the company. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Caris Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.33.

Caris Life Sciences Stock Up 8.0%

CAI opened at $24.58 on Friday. Caris Life Sciences, Inc. has a 12 month low of $14.19 and a 12 month high of $42.50. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. The business’s 50-day moving average price is $18.27 and its 200-day moving average price is $18.52. The company has a market cap of $6.95 billion, a P/E ratio of 68.28 and a beta of 0.68.

Caris Life Sciences declared that its Board of Directors has approved a stock repurchase plan on Monday, June 8th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to purchase up to 2.1% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its stock is undervalued.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.